Table 3 Chemoresponse assay results (expressed as a continuous variable (RI score)) for metachronous tumor pairs
From: In vitro chemoresponse in metachronous pairs of gyneclologic cancers
Number of pairs | Primary median (IQR) RI SCORE | Recurrent median (IQR) RI SCORE | p | |
|---|---|---|---|---|
Carboplatin | 46 | 5.59(4.89,6.09) | 5.32(4.94,5.80) | 0.28 |
Carboplatin/Gemcitabine | 35 | 5.71(5.16,6.30) | 5.90(5.40,6.36) | 0.33 |
Carboplatin/Paclitaxel | 41 | 6.17(5.15,6.67) | 5.92(5.25,6.29) | 0.48 |
Cisplatin | 42 | 5.40(4.66,5.77) | 5.38(4.67,5.68) | 0.80 |
Docetaxel | 42 | 5.26(4.74,5.75) | 4.96(4.43,5.42) | 0.14 |
Doxorubicin | 49 | 5.17(4.20,5.58) | 5.11(4.56,5.56) | 0.82 |
Etoposide | 39 | 5.49(4.66,6.00) | 5.41(4.83,5.84) | 0.85 |
Gemcitabine | 48 | 5.27(4.46,5.55) | 5.11(4.68,5.55) | 0.64 |
Ifosfamide | 30 | 5.58(5.32,5.80) | 5.68(5.25,5.87) | 0.90 |
Paclitaxel | 47 | 5.59(4.99,6.21) | 5.30(4.80,5.74) | 0.08 |
Topotecan | 52 | 5.39(4.65,5.74) | 5.20(4.54,5.65) | 0.99 |